European Expedited Programs & Harnessing HTA
Executive Summary
European regulators are exploring their interactions with health technology appraisal bodies to improve expedited programs that aim to get medicines to patients more quickly.
You may also be interested in...
UK Voluntary Pricing Deal: Commercial Framework To Better Align With New Regulatory Pathways
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
Hits, Misses & Key Firsts For EMA’s PRIME Scheme
The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.